John Hussman's ALNY Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 6.3K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $0, representing 0.00% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, John Hussman has maintained this position in ALNY for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q2 2025, reducing 2.1K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2025 | +8,400 | New Buy | 8,400 | $270.02 |
| Q2 2025 | -2,100 | Reduce 25.00% | 6,300 | $326.09 |
| Q3 2025 | -6,300 | Sold Out | 6,300 | $0.00 |
John Hussman's Alnylam Pharmaceuticals Investment FAQs
John Hussman first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q1 2025, acquiring 8,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Alnylam Pharmaceuticals, Inc. (ALNY) for 3 quarters since Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q1 2025, adding 8,400 shares worth $2.27 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 6,300 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $0. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.00% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 8,400 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.